A message from Suzanne McGurn, President and CEO, CADTH

On behalf of CADTH and our Board of Directors, I’m pleased to share the CADTH Annual Report for 2022–2023.

The theme of this year’s report, Ahead of the Curve, aligns with our strategic plan and our efforts to shape a future-ready health system in Canada.  

As CADTH continues along the path of strategic transformation, we’re working hard to align the evidence products we deliver with the priority needs of decision-makers in Canada. As part of this work, CADTH has made the decision to retire Reference Lists as a standard offering in our evidence product line.

Reference Lists were delivered through our Rapid Response Service in the form of reports that provided a bibliographic list of references or a summary of the abstracts from the references.

The CADTH Weekly Summary is an email newsletter sent every Thursday to bring subscribers important notifications about CADTH drug reimbursement reviews, including input and feedback opportunities, the publication of draft and final drug reimbursement recommendations, and procedural updates.

New committee will trial novel  approaches to drug reviews and expand support for decision-makers to unleash the value of drugs across their lifespan.

CADTH, Canada’s drug and health technology agency, announces the creation and inaugural membership of a new Formulary Management Expert Committee as a 1-year pilot program.

Today, CADTH is communicating a series of improvements that will further our ambition to innovate in the field of health technology assessment (HTA), adapt to changing regulatory and reimbursement environments, and improve the pathway that brings effective drugs to patients across Canada.